Professional
Added to YB: 2024-09-10
Pitch date: 2024-06-30
RGEN [bullish]
Repligen Corporation
+24.97%
current return
Author Info
No bio for this author
Company Info
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Market Cap
$8.6B
Pitch Price
$125.94
Price Target
N/A
Dividend
N/A
EV/EBITDA
51.33
P/E
6.0K
EV/Sales
12.03
Sector
Life Sciences Tools and Services
Category
N/A
Alger Small Cap Focus Fund Porfolio Holding - Repligen Corporation
RGEN: CEO Hunt stepping down, sparking investor concern. COO Loeillot to take over. Guidance unconfirmed during transition. Long-term fundamentals remain strong with experienced team and robust bioprocessing tech portfolio for large molecule drug manufacturing. 4 key areas: Filtration, Chromatography, Process Analytics, Proteins.
Read full article (1 min)